Mangoceuticals (MGRX) EBIAT (2023 - 2025)
Mangoceuticals (MGRX) has disclosed EBIAT for 3 consecutive years, with -$2.8 million as the latest value for Q4 2025.
- Quarterly EBIAT fell 42.1% to -$2.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$20.6 million through Dec 2025, down 137.07% year-over-year, with the annual reading at -$20.6 million for FY2025, 137.08% down from the prior year.
- EBIAT hit -$2.8 million in Q4 2025 for Mangoceuticals, up from -$7.6 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$1.8 million in Q3 2023 to a low of -$7.6 million in Q3 2025.
- Historically, EBIAT has averaged -$3.2 million across 3 years, with a median of -$2.5 million in 2023.
- Biggest five-year swings in EBIAT: grew 24.12% in 2024 and later crashed 280.97% in 2025.
- Year by year, EBIAT stood at -$2.6 million in 2023, then increased by 24.12% to -$1.9 million in 2024, then crashed by 42.1% to -$2.8 million in 2025.
- Business Quant data shows EBIAT for MGRX at -$2.8 million in Q4 2025, -$7.6 million in Q3 2025, and -$5.4 million in Q2 2025.